Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16827670 | 0.78 | POLB (0.50) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL16827770 | 0.78 | POLB (0.50) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL6004013 | 0.77 | MMP13 (0.42) | LMNAMAPTPIK3CDENPP2 | |
| SCHEMBL6004607 | 0.76 | ENPP2 (0.38) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL4871002 | 0.76 | ENPP2 (0.39) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL4761315 | 0.71 | NR1H2 (0.46) | LMNAMAPTENPP2 | |
| SCHEMBL6005068 | 0.71 | ENPP2 (0.38) | LMNAMAPTPOLBENPP2 | |
| SCHEMBL16845866 | 0.70 | GPR119 (0.52) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL6003951 | 0.69 | NR1H2 (0.47) | LMNAMAPTPIK3CDENPP2 | |
| SCHEMBL6004473 | 0.69 | NR1H2 (0.36) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | TP53 1429/4885THRB 1088/4885LMNA 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.